Use of @entity1667 in XXXX following @entity583 . Hemodynamic and metabolic effects.

@entity1667 @entity1 @entity5691 @entity1188 @entity880 @entity583
Hemodynamic and metabolic effects of @entity1667 were investigated in a double-blind study of 28 @entity1 with @entity583 ( @entity583 ), confirmed by unequivocal electrocardiographic and enzyme changes. Measurements were performed prior to and at 1.5, 3, 4, 4.5, 12 and 24 hours following infusion of @entity1667 (13 @entity1 ) or placebo (15 @entity1 ). Although systemic vascular resistance decreased from 1,750 to 1,420 dynes . sec . cm-5 (p less than .001) and cardiac index increased from 2.77 to 3.10 L/min/m2 (p less than .02) between 0 and 4.5 hours, an abnormal increase in blood @entity880 was observed in 10 of the 13 @entity1 following administration of @entity1667 (3.0 vs 1.2 mM/L, p less than .001). @entity880 elevation appeared one hour after infusion of @entity1667 , was maximal at 12 hours, and persisted for more than 24 hours. There was no significant change in blood @entity880 in placebo treated @entity1 . A transient but significant decrease in plasma volume was also observed following infusions of @entity1667 . The elevation of blood @entity880 could not be explained by the reduction in plasma volume since the most striking increases in @entity880 were observed 12 hours following the initial infusion of @entity1667 when the plasma volume was returning to the control value. No significant differences in other hemodynamic or metabolic parameters, @entity1188 size or @entity1 survival were observed between the two groups. We conclude that the hemodynamic benefits of glucocorticoids characterized by @entity5691 and lowered systemic vascular resistance are counterbalanced by the potentially unfavorable conditions of @entity880 elevation and volume depletion.
